1. Refereed Papers (2006-2011)

-1.Zhang R, Wu X, Yalowich JC and Hasinoff BB, Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents. Bioorganic & Medicinal Chemistry 19: 7023-7032, 2011. [MOP-13748]

0.Wu X, Yalowich JC and Hasinoff BB, Cadmium is a catalytic inhibitor of DNA topoisomerase II. Journal of Inorganic Biochemistry 105: 833-838, 2011. [MOP-13748].

1.Herman EH, Knapton A, Rosen E, Thompson K, Rosenzweig B, Estis J, Agee S, Lu QA, Todd JA, Lipshultz S, Hasinoff BB and Zhang J, A Multifaceted Evaluation of Imatinib-induced Cardiotoxicity in the Rat. Toxicologic Pathology 39: 1091-1106, 2011. [MOP-79294]

2.Zhang R, Wu X, Guziec LJ, Guziec F, Jr., Chee G-L, Yalowich JC and Hasinoff BB, Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents. Bioorganic & Medicinal Chemistry 18: 3974-3984, 2010. [MOP-13748]

3.O'Hara KA, Dmitrienko GI and Hasinoff BB, Kinamycin F downregulates cyclin D3 in human leukemia K562 cells. Chemico-Biological Interactions 184: 396-402, 2010. [MOP-13748]

4.Hasinoff BB and Patel D, The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicology and Applied Pharmacology 249: 132-139, 2010. [MOP-79294]

5.Hasinoff BB and Patel D, Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. Cardiovascular Toxicology 10: 1-8, 2010. [MOP-79294]

6.Hasinoff BB, The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicology and Applied Pharmacology 244: 190-195, 2010. [MOP-79294]

7.Chee G-L, Yalowich JC, Bodner A, Wu X and Hasinoff BB, A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II. Bioorganic & Medicinal Chemistry 18: 830-838, 2010. [MOP-13748]

8.Wang GQ, Burczynski FJ, Hasinoff BB, Zhang KD, Lu Q and Anderson JE, Development of a nitric oxide-releasing analogue of the muscle relaxant guaifenesin for skeletal muscle satellite cell myogenesis. Molecular Pharmaceutics 6: 895-904, 2009. [MOP-79294]

9.Martin E, Thougaard AV, Grauslund M, Jensen PB, Bjorkling F, Hasinoff BB, Sehested M and Jensen LH, Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology 255: 72-79, 2009. [MOP-13748]

10.Hasinoff BB, Zhang R, Wu X, Guziec LJ, Guziec FS, Jr., Marshall K and Yalowich JC, The structure-based design, synthesis and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds. Bioorganic & Medicinal Chemistry 17: 4575-4582, 2009. [MOP-13748]

11.Hasinoff BB and Patel D, The iron chelator Dp44mT does not protect myocytes against doxorubicin. Journal of Inorganic Biochemistry 103: 1093-1101, 2009. [MOP-79294]

12.Wu X, Liang H, O'Hara K, Yalowich JC and Hasinoff BB, Thiol-modulated mechanisms of the cytotoxicity of thimerosal and inhibition of DNA topoisomerase IIα. Chemical Research in Toxicology 21: 483-493, 2008. [MOP-13748]

13.Wang GQ, Gong Y, Burczynski FJ and Hasinoff BB, Cell lysis with dimethyl sulfoxide produces stable homogeneous solutions in the dichlorofluorescin oxidative stress assay. Free Radical Research 42: 435-441, 2008. [MOP-79294]

14.Schroeder PE, Patel D and Hasinoff BB, The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites. Drug Metabolism and Disposition 36: 1780-1785, 2008. [MOP-79294]

15.Liang H, Wu X, Yalowich JC and Hasinoff BB, A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIα inhibitors. Molecular Pharmacology 73: 686-696, 2008. [MOP-13748]

16.Hasinoff BB, Patel D and O'Hara KA, Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Molecular Pharmacology 74: 1722-1728, 2008. [MOP-79294]

17.Hasinoff BB, The use of dexrazoxane for the prevention of anthracycline extravasation injury. Expert Opinion on Investigational Drugs 17: 217-223, 2008. [MOP-79294]

18.Hasinoff BB, Liang H, Wu X, Guziec LJ, Guziec FS, Jr. and Yalowich JC, The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds. Bioorganic & Medicinal Chemistry 16: 3959-3968, 2008. [MOP-13748]

19.Smith SI, Guziec LJ, Guziec FS, Hasinoff BB and Brodbelt JS, Evaluation of relative DNA binding affinities of anthrapyrazoles by electrospray ionization mass spectrometry. Journal of Mass Spectrometry 42: 681-688, 2007. [MOP-13748]

20.O'Hara K, Wu X, Patel D, Liang H, Yalowich JC, Chen N, Goodfellow V, Adedayo O, Dmitrienko GI and Hasinoff BB, Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F. Free Radical Biology & Medicine 43: 1132-1144, 2007. [MOP-13748]

21.Liu W, Buck M, Chen N, Shang M, Taylor NJ, Asoud J, Wu X, Hasinoff BB and Dmitrienko GI, Total synthesis of isoprekinamcyin: structural evidence for enhanced diazonium ion character and growth inhibitory activity towards cancer cells. Organic Letters 9: 2915-2918, 2007. [MOP-13748]

22.Hasinoff BB, Dexrazoxane use in the prevention of anthracycline extravasation injury. Hospital Pharmacy Europe 32: 69-70, 2007. [MOP-79294]

23.Hasinoff BB and Herman EH, Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovascular Toxicology 7: 140-144, 2007. [MOP-79294]

24.Hasinoff BB, Patel D and Wu X, The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent. Cardiovascular Toxicology 7: 19-27, 2007. [MOP-79294]

25.Begleiter A, Leith MK, Patel D and Hasinoff BB, Role of NADPH cytochrome P450 reductase in activation of RH1. Cancer Chemotherapy and Pharmacology 60: 713-723, 2007. [MOP-79294]

26.Liang H, Wu X, Guziec LJ, Guziec FS, Jr., Larson KK, Lang J, Yalowich JC and Hasinoff BB, A structure-based 3D-QSAR study of anthrapyrazole analogs of the anticancer agents losoxantrone and piroxantrone. Journal of Chemical Information and Modeling 46: 1827-1835, 2006. [MOP-13748]

27.Jensen LH, Liang H, Shoemaker RH, Grauslund M, Sehested M and Hasinoff BB, A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIα by substituted purine analogs. Molecular Pharmacology 70: 1503-1513, 2006. [MOP-13748]

28.Hasinoff BB and Begleiter A, The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells. Free Radical Research 40: 974-978, 2006. [MOP-79294]

29.Hasinoff BB, Dexrazoxane use in the prevention of anthracycline extravasation injury. Future Oncology 2: 15-20, 2006. [MOP-79294]

30.Hasinoff BB, Wu X, Yalowich JC, Goodfellow V, Laufer RS, Adedayo O and Dmitrienko GI, Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects. Anti-Cancer Drugs 17: 825-837, 2006. [MOP-13748]

31.Hasinoff BB, Wu X, Begleiter A, Guziec L, Guziec FS, Jr., Giorgianni A, Yang S, Jiang Y and Yalowich JC, Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II. Cancer Chemotherapy and Pharmacology 57: 221-233, 2006. [MOP-13748]

32.Begleiter A, Lin D, Larson KK, Lang J, Wu X, Cabral T, Taylor H, Guziec LJ, Kerr PD, Hasinoff BB and Guziec F, Structure-activity studies with cytotoxic anthrapyrazoles. Oncology Reports 15: 1575-1580, 2006. [MOP-13748]

4. Book Chapters (1990-2011)

1.Hasinoff BB, The pharmacology of dexrazoxane: iron chelating prodrug and topoisomerase II inhibitor. In: Razoxane and Dexrazoxane - Two Multifunctional Agents (Eds. Hellmann K and Rhomberg W). Springer, Dordrecht, 2010.

2.Wang HH, Scherbarth S, McIntosh AR, Hasinoff BB, Rector ES, Ahmed N, Nance DM and Orr FW, Regulation of cancer metastasis to the liver by the hepatic microvasculature. In: Cells of the Hepatic Sinusoid, Vol. 8. Kupffer Cell Foundation, Leiden, 2000.

5. Invited Talks Given at International Conferences (2002-2011)

1.Hasinoff BB, The cardiotoxicity and myocyte damage caused by small molecule anticancer kinase inhibitors is correlated with their lack of target specificity [Lettura Magistrale]. Cardiovascular Complications in Oncology: Yesterday and Today (Naples, Italy), October 28-29, 2010. [MOP-79294]

2.Hasinoff BB, 3D-QSAR based design of novel inhibitors of topoisomerase II. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, (Boston, MA), November 15-19, 2009. [MOP-13748]

3.Hasinoff BB, Dexrazoxane: How it works in cardiac and tumor cells. International Workshop on Anthracycline Cardiotoxicity: Molecular Mechanisms and Clinical Correlates (Como, Italy), October 20-21, 2006. [MOP-13748]

4.Hasinoff BB, Mechanism of the prevention of iron-based doxorubicin cardiotoxicity by dexrazoxane. 7th International Symposium on Chelating Agents in Biomedicine, Toxicology and Therapeutics (Pilsen, Czech Republic), July 8-11, 2004. [MOP-79294]

5.Hasinoff BB, The antioxidant activity of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187). International Symposium on Reactive Oxygen and Nitrogen Species (St. Petersburg, Russia) July 8-12, 2002. [MOP-79294]

6. Abstracts (2006-2011)

1.Wu X, Yalowich JC and Hasinoff BB, The anticancer kinase inhibitor dovitinib (TKI258) may have multiple modes of action because it also binds DNA and inhibits topoisomerase I and topoisomerase IIα. American Association for Cancer Research Abstract no. 2530, 2011. [MOP-13748]

2.Hasinoff BB, Patel D and Wu X, Lapatinib in combination with doxorubicin is highly damaging to cardiac myocytes. American Association for Cancer Research Abstract no. 3576, 2011. [MOP-13748]

3.Chee G-L, Bhattarai B, Al-Rashid S, Yalowich JC and Hasinoff BB, Bethoxazin is a potent inhibitor of DNA topoisomerase II. American Association for Cancer Research, 2011. [MOP-13748]

4.Zhang R, Wu X, Chee G-L, Guziec LJ, Guziec F, Yalowich JC and Hasinoff BB, Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents. American Association for Cancer Research Abstract # 3509: 342, 2010. [MOP-13748]

5.Wu X, Zhang R, Guziec L, Guziec F, Yalowich JC and Hasinoff BB, The molecular docking-based design and biological evaluation of a novel series of bisintercalating DNA-binding bisanthrapyrazole compounds containing amine linkers. American Association for Cancer Research Abstract # 3510: 342, 2010. [MOP-13748]

6.Hasinoff BB, The cardiotoxicity and myocyte damage caused by small molecule anticancer kinase inhibitors is correlated with their lack of target specificity. Western Canada Medicinal Chemistry Workshop 11, 2010. [MOP-79294]

7.Hasinoff BB, The cardiotoxicity and myocyte damage caused by small molecule anticancer kinase inhibitors is correlated with their lack of target specificity. Cardiovascular Complications in Oncology: Yesterday and Today (Naples, Italy), 2010. [MOP-79294]

8.Hasinoff BB and Patel D, The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. American Association for Cancer Research Abstract no. 2602: 283, 2010. [MOP-13748]

9.Chee G-L, Yalowich JC and Hasinoff BB, A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II. American Association for Cancer Research Abstract no. 3508: 342, 2010. [MOP-13748]

10.Zhang R, Wu X, Guziec F, Guziec L and Hasinoff BB, The molecular docking-based design and biological evaluation of a novel series of amide-linked bisintercalating DNA-binding bisanthrapyrazole compounds. American Association for Cancer Research 50: Abstract no. 654, 2009. [MOP-13748]

11.Wu X and Hasinoff BB, Sulfhydryl-modulated mechanisms of the cytotoxicity of cadmium and inhibition of DNA topoisomerase IIα. American Association for Cancer Research 50: Abstract no.1692, 2009. [MOP-13748]

12.Hasinoff BB, 3D-QSAR based design of novel inhibitors of topisomerase II. AACR-NCI-EORTC International Conference; Molecular Targets and Cancer Therapeutics Abstract Number: CN08-01: 342-343, 2009. [MOP-13748]

13.Hasinoff BB, The iron chelator Dp44mT does not protect myocytes against doxorubicin. 6th Meeting of the Oxidative Stress Consortium 49, 2009. [MOP-79294]

14.Hasinoff BB and Patel D, Mechanisms of myocyte cytotoxicity induced by the cardiotoxic anticancer serine/threonine multikinase inhibitor sorafenib. American Association for Cancer Research 50: Abstract no. 5446, 2009. [MOP-79294]

15.Wu X, Yalowich JC and Hasinoff BB, Effects of brilliant green on human erythroleukemic K562 and breast adenocarcinoma MCF7 cell growth and on inhibition of human topoisomerase IIα. Proceedings of the American Association for Cancer Research 49: 137, 2008. [MOP-13748]

16.O'Hara K, Dmitrienko GI and Hasinoff BB, Cyclin D3 is down-regulated by kinamycin F in human chronic myelogenous leukemia K562 cells. Proceedings of the American Association for Cancer Research 49: 133, 2008. [MOP-79294]

17.Hasinoff BB, Liang H, Wu X and Yalowich JC, A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIα inhibitors. Proceedings of the American Association for Cancer Research 49: 137, 2008. [MOP-13748]

18.Wu X, Liang H, O'Hara K, Yalowich JC and Hasinoff BB, Effects of the organic mercury compound thimerosal on human erythroleukemic K562 and colon carcinoma HCT116 cell growth and on inhibition of human topoisomerase II. American Association for Cancer Research 48: 188, 2007. [MOP-13748]

19.Wang GQ, Hasinoff BB and Liang H, Effect of liver fatty acid binding protein on the efficacy of peroxisome proliferator-activated receptor alpha agonists: A molecular modeling docking analysis. The AAPS Journal 9: Abstract M1085, 2007. [MOP-79294]

20.O'Hara K, Wu X, Patel D, Liang H, Yalowich JC, Goodfellow V, Adedayo O, Dmitrienko GI and Hasinoff BB, Reductive and oxidative activation mechanisms of the potent cancer cell growth inhibitory effects of the azo-containing bacterial metabolite kinamycin F. American Association for Cancer Research 48: 363-364, 2007. [MOP-79294]

21.Marshall K, Liang H, Wu X, Hasinoff BB, Guziec LJ and Guziec FS, Preparations and biological evaluation of new anthrapyrazoles and bisanthrapyrazoles. American Chemical Society Proceedings, Boston, MA, Aug 19-23, 2007 Abstract 314, 2007. [MOP-13748]

22.Liang H, Wu X, Guziec L, Guziec F, Marshall K and Hasinoff BB, The molecular docking-based design and biological evaluation of a novel series of bisintercalating DNA-binding bisanthrapyrazole compounds. American Association for Cancer Research 48: 1121, 2007. [MOP-13748]

23.Hasinoff BB, O'Hara K, Wu X, Liang H and Dmitrienko GI, Reductive and oxidative activation mechanisms of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F. 5th Meeting of the Canadian Oxidative Stress Consortium 5: 6, 2007. [MOP-79294]

24.Hasinoff BB, How the anthracycline cardioprotective drug dexrazoxane works in cardiac and tumor cells. Canadian Society for Chemistry Annual Meeting, Winnipeg May 26-30, 2007 Abstract # 997, 2007. [MOP-79294]

25.Wu X, Liang H and Hasinoff BB, NSC101612 potently inhibits tumor cell growth and is a topoisomerase IIα catalytic inhibitor. Proceedings of the American Association for Cancer Research 47: 1301, 2006. [MOP-13748]

26.Wang GQ, Burczynski FJ and Hasinoff BB, An improved method to quantify oxidative stress in cells with the dichlorofluorescein assay. Free Radical Biology & Medicine 41 S1: S104, 2006. [MOP-79294]

27.Wang GQ, Hasinoff BB, Liang H, Burczynski FJ and Anderson JE, Development a new nitric oxide-releasing compound for activation of skeletal muscle satellite cells. Free Radical Biology & Medicine 41 S1: S56, 2006. [MOP-79294]

28.Smith S, Brodbelt JS, Guziec F and Hasinoff BB, DNA binding of new anthrapyrazoles by ESI-MS-MS. 54th ASMS Conference on Mass Spectrometry Number 411, 2006. [MOP-13748]

29.O'Hara K, Hasinoff BB, Patel D, Goodfellow V, Laufer RS, Adedayo O and Dmitrienko GI, Molecular mechanisms of the growth inhibitory effects of the bacterial metabolites kinamycin A and C. Proceedings of the American Association for Cancer Research 47: 1304, 2006. [MOP-13748]

30.Liang H, Hasinoff BB, Mashina R and Nitiss JL, Identification of possible etoposide binding sites on yeast DNA topoisomerase II using molecular modeling. Proceedings of the American Association for Cancer Research 47: 457, 2006. [MOP-13748]

31.Jensen LH, Liang H, Shoemaker RH, Sehested M and Hasinoff BB, Substituted purine analogs as catalytic topoisomerase II inhibitors - a 3D QSAR study. Proceedings of the American Association for Cancer Research 47: 1301, 2006. [MOP-13748]

32.Hasinoff BB, Dexrazoxane: How it works in cardiac and tumor cells. International Workshop on Anthracycline Cardiotoxicity: Molecular Mechanisms and Clinical Correlates (Como, Italy), October 20-21, 2006. [MOP-79294]